Sep 20, 2021 / 03:00PM GMT
Joshua Brodsky - Alnylam Pharmaceuticals, Inc. - Director of IR & Corporate Communications
Good morning, everyone, and thank you for joining us for today's RNAi Roundtable, in which we'll be discussing several of our liver-directed RNAi therapeutic pipeline programs. I'm Josh Brodsky, Senior Director of Investor Relations and Corporate Communications at Alnylam. I'm joined today by my colleagues, Eric Green, Senior Vice President of Development programs; Tanya Fischer, Vice President of Clinical Development; and Josh Friedman, Senior Director of Clinical Research.
Today's RNAi roundtable is part of a series of roundtable webinars that we're hosting this summer and fall to review progress across our various programs. Today's event is expected to run approximately 1 hour. Eric will moderate a Q&A session at the conclusion of the presentations. (Operator Instructions) As a reminder, we will be making forward-looking statements during this webinar, and we encourage you to read our most recent SEC filings for a more complete discussion of risk factors.
Now before I hand it over to
Alnylam Pharmaceuticals Inc “RNAi Roundtable” Webcast Series: Liver-Directed RNAi Pipeline Programs Transcript
Sep 20, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers